Bulls Pick Up Merck Stock After Surprise Quarterly Win
Merck & Co Inc (NYSE:MRK) announced surprise fourth-quarter profits of 3 cents per share earlier, as well as revenue of $14.63 billion, both of which easily surpassed analysts' expectations.
Merck (MRK) Beats Q4 Earnings Estimates
Merck (MRK) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.09 per share. This compares to earnings of $1.62 per share a year ago.
Merck results beat expectations as top drugs Keytruda, Gardasil post strong sales
CNBC's Mike Santoli reports on the company's quarterly earnings results.
Merck Stock Jumps as Earnings Beat, Guidance Ahead of Wall Street Expectations
Merck posted a 3-cent a share loss on revenue of $14.6 billion in the fourth quarter. Analysts surveyed by FactSet had expected Merck to report an 11-cent loss on revenue of $14.5 billion.
Merck posts better-than-expected quarterly results on soaring Keytruda sales
Merck & Co on Thursday reported better-than-expected fourth-quarter results on strong sales of its cancer immunotherapy Keytruda, now the world's biggest selling prescription medicine.
Merck's fourth-quarter results top estimates, fueled by key cancer drugs and vaccines
Merck & Co. Inc. on Thursday reported fourth-quarter earnings and sales that beat analysts' expectations, powered by strong growth in cancer and vaccine products.
Merck results beat expectations as top drugs Keytruda, Gardasil post strong sales
Merck still posted a quarterly loss due to previously announced charges associated with its cancer drug collaboration deal with Daiichi Sankyo.
Can Merck (MRK) Keep the Beat Streak Alive in Q4 Earnings?
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports fourth-quarter earnings.
This 1 Bullish Move by Merck Could Drive Growth for Years to Come
Merck plans to buy biotech Harpoon Therapeutics. Harpoon's platform is powerful, and it could produce many opportunities.
Merck (MRK) Laps the Stock Market: Here's Why
Merck (MRK) concluded the recent trading session at $119.43, signifying a +0.45% move from its prior day's close.
Merck's Keytruda combo gets FDA nod for expanded use in cervical cancer
The U.S. Food and Drug Administration (FDA) on Friday approved the expanded use of Merck & Co's blockbuster immunotherapy Keytruda in combination with chemoradiotherapy to treat newly diagnosed pat...
Merck (MRK) to Strengthen Cancer Pipeline With Harpoon Buyout
Merck's (MRK) Harpoon buyout is expected to strengthen its oncology pipeline by adding the latter's lead pipeline candidate, HPN328, a T cell engager being studied for SCLC and neuroendocrine tumors.
Merck & Co., Inc. (MRK) Presents at JPMorgan 42nd Annual Healthcare Conference (Transcript)
Merck & Co., Inc. (MRK) Presents at JPMorgan 42nd Annual Healthcare Conference (Transcript)
Merck (MRK) Advances But Underperforms Market: Key Facts
Merck (MRK) reachead $117.38 at the closing of the latest trading day, reflecting a +0.14% change compared to its last close.
Merck Stock's Rally Could Extend to Record Highs
The shares of Merck & Co Inc (NYSE:MRK) are already 7.3% higher since the start of the year, and earlier hit a six-month high of $117.89 before turning lower.
Related Companies